This article caught my eye as just a couple of weeks ago I went to a lecture on immunology and the treatment of infectious diseases.
What the doctor giving the talk covered, more or less, debunks this article as taking what is undoubtedly a truism of the development of superbugs and weaving an apocalypse out of it when actually about the only thing stopping us developing new and effective treatments for bacteriological infections is that it is, astoundingly, not very profitable. The lead time is long and the pay-off tail is short because, yes, bacteria do become resistant pretty quickly to each new treatment so drug companies don't have long to make money on an antibiotic before it become ineffective (tho', something that is not often reported, they can become effective again after a while as the bacteria dump the defences they don't need any more when a given antibiotic stops being administered for a few decades).
http://www.wired.com/wiredscience/2013/11/end-abx/
What the doctor giving the talk covered, more or less, debunks this article as taking what is undoubtedly a truism of the development of superbugs and weaving an apocalypse out of it when actually about the only thing stopping us developing new and effective treatments for bacteriological infections is that it is, astoundingly, not very profitable. The lead time is long and the pay-off tail is short because, yes, bacteria do become resistant pretty quickly to each new treatment so drug companies don't have long to make money on an antibiotic before it become ineffective (tho', something that is not often reported, they can become effective again after a while as the bacteria dump the defences they don't need any more when a given antibiotic stops being administered for a few decades).
http://www.wired.com/wiredscience/2013/11/end-abx/